Abstract: TH-PO0509
Efficacy and Safety of Sofosbuvir Plus Velpatasvir Combination for Treatment of Patients with Chronic Hepatitis-C Infection (All Genotypes) and ESRD on Hemodialysis
Session Information
- Dialysis: Novel Therapeutics and Medication Management
November 06, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Dialysis
- 801 Dialysis: Hemodialysis and Frequent Dialysis
Author
- Savani, Krupa Hareshkumar, Savani Kidney Care Centre, Surat, Gujarat, India
Background
Treatment of Hepatitis C infection in patients with end-stage renal disease on regular hemodialysis is difficult, and treatment options are limited. This study evaluated the safety and efficacy of sofosbuvir plus velpatasvir in patients with Hepatitis C virus (HCV) infection. We treated Hepatitis C infected patients on regular hemodialysis (genotype 1 to 6 positive). All patients received a fixed-dose combination of sofosbuvir (400 mg) and velpatasvir (100 mg) once daily for 12 weeks.
Methods
In the hemodialysis unit, a total of 53 patients (39 male and 14 female, aged between 34 years to 71 years) were infected with Hepatitis C between January 2022 and March 2025. Of these, 41 patients had genotype 1, 6 had genotype 3, 3 had genotype 2, and one patient each had genotype 4, genotype 5, and genotype 6. All patients were treated orally with a fixed-dose combination of sofosbuvir (400 mg) and velpatasvir (100 mg) once daily for 12 weeks. Routine clinical and laboratory data were collected at baseline and during treatment. The primary outcome was a sustained virological response at week 12 (SVR12).
Results
The therapy was well tolerated in all 53 patients, and no one discontinued the treatment due to side effects. The most common adverse events were headache (12%), fatigue (10%), nausea (9%), and vomiting (9%). Comparison of laboratory values at baseline and at nadir levels during treatment revealed no significant changes in haemoglobin, platelet count, ALT, or bilirubin levels. Out of 53 patients, 52 had undetectable HCV RNA at the end of treatment. Only one patient (with genotype 2) had detectable HCV RNA at the end of treatment. Additionally, no cardiac or hepatobiliary toxicity was observed during the treatment.
Conclusion
Treatment with a fixed-dose combination of sofosbuvir (400 mg) and velpatasvir (100 mg) for chronic Hepatitis C infection (all genotypes) in patients with end-stage renal disease on regular hemodialysis was safe and highly effective. No significant adverse events were observed during the period of treatment.